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ABSTRACT: Microbiology is a rapidly changing field. As new researches and
experiences broaden our knowledge, changes in the approach to diagnosis and therapy have
become necessary and appropriate. Recommended dosage of drugs, method and duration of
administration, as well as contraindications to use, evolve over time all drugs. Over the last
2 decades, Candida species have emerged as causes of substantial morbidity and mortality
in hospitalized individuals. Isolation of Candida from blood or other sterile sites, excluding
the urinary tract, defines invasive candidiasis. Candida species are currently the fourth most
common cause of bloodstream infections (that is, candidemia) in U.S. hospitals and occur
primarily in the intensive care unit (ICU), where candidemia is recognized in up to 1% of
patients and where deep-seated Candida infections are recognized in an additional 1 to 2%
of patients. Despite the introduction of newer anti-Candida agents, invasive candidiasis con-
tinues to have an attributable mortality rate of 40 to 49%; excess ICU and hospital stays of
12.7 days and 15.5 days, respectively, and increased care costs. Postmortem studies suggest
that death rates related to invasive candidiasis might, in fact, be higher than those described
because of undiagnosed and therefore untreated infection. The diagnosis of invasive candi-
diasis remains challenging for both clinicians and microbiologists. Reasons for missed diag-
noses include nonspecific risk factors and clinical manifestations, low sensitivity of micro-
biological culture techniques, and unavailability of deep tissue cultures because of risks
associated with the invasive procedures used to obtain them. Thus, a substantial proportion
of invasive candidiasis in patients in the ICU is assumed to be undiagnosed and untreated.
Yet even when invasive candidiasis is diagnosed, culture diagnosis delays treatment for 2 to
3 days, which contributes to mortality. Interventions that do not rely on a specific diagnosis
and are implemented early in the course of Candida infection (that is, empirical therapy) or
before Candida infection occurs (that is, prophylaxis) might improve patient survival and
may be warranted. Selective and nonselective administration of anti-Candida prophylaxis is
practiced in some ICUs. Several trials have tested this, but results were limited by low stati-
stical power and choice of outcomes. Thus, the role of anti-Candida prophylaxis for pa-
tients in the ICU remains controversial. Initiating anti-Candida therapy for patients in the
ICU who have suspected infection but have not responded to antibacterial therapy (empi-
rical therapy) is practiced in some hospitals. This practice, however, remains a subject of
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COLOGY AND MYCOSES held from 18—20. April 2007. in Novi Sad.considerable debate. These patients are perceived to be at higher risk from invasive candi-
diasis and therefore are likely to benefit from empirical therapy. Nonetheless, empirical
anti-Candida therapies have not been evaluated in a randomized trial and would share
shortcomings that are similar to those described for prophylactic strategies. Current treat-
ment guidelines by the Infectious Diseases Society of America (IDSA) do not specify
whether empirical anti-Candida therapy should be provided to immunocompetent patients.
If such therapy is given, IDSA recommends that its use should be limited to patients with
Candida colonization in multiple sites, patients with several other risk factors, and patients
with no uncorrected causes of fever. Without data from clinical trials, determining an opti-
mal anti-Candida strategy for patients in the ICU is challenging. Identifying such a strategy
can help guide clinicians in choosing adequate therapy and may improve patient outcomes.
In our study, we developed a decision analytic model to evaluate the cost-effectiveness of
empirical anti-Candida therapy given to high-risk patients in the ICU, defined as those with
altered temperature (fever or hypothermia) or unexplained hypotension despite 3 days of an-
tibacterial therapy in the ICU.
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INTRODUCTION
Background: Candida species are ubiquitous fungi and are the most
common fungal pathogens that affect humans. The growing problem of muco-
sal and systemic candidiasis reflects the enormous increase in the pool of pati-
ents at risk and the increased opportunity that exists for Candida species to in-
vade tissues normally resistant to invasion. Candida species are true opportuni-
stic pathogens that exploit recent technological advances to gain access to the
circulation and deep tissues (1).
The increased prevalence of local and systemic disease caused by Candi-
da species has resulted in numerous new clinical syndromes, primarily depen-
dent on the immune status of the host. Candida species produce a wide spec-
trum of diseases, ranging from superficial mucocutaneous disease to invasive
illnesses, such as hepatosplenic candidiasis, Candida peritonitis, and systemic
candidiasis. Management of serious and life-threatening invasive candidiasis
remains severely hampered by delays in diagnosis and the lack of reliable di-
agnostic methods that allow detection of both fungemia and tissue invasion by
Candida species.
Advances in medical technology, chemotherapeutics, cancer therapy, and
organ transplantation have had a major impact on reducing the morbidity and
mortality of life-threatening disease. Patients who are critically ill and in medi-
cal and surgical ICUs have been the prime targets for opportunistic nosoco-
mial fungal infections, primarily due to Candida species. Studies suggest that
the problem is not under control and, that it is, in fact, worsening. On a daily
basis, virtually all physicians are confronted with a positive Candida isolate
obtained from one or more various anatomical sites. High-risk areas for Candi-
da infection include neonatal, pediatric, and adult ICUs, both medical and sur-
gical. Candida infections can involve any anatomical structure (2).
Pathophysiology: Candida species are yeastlike fungi that can form true
hyphae and pseudohyphae. For the most part, Candida species are confined to
human and animal reservoirs. However, they are frequently recovered from the
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ors, respirators, and medical personnel. They are also normal commensals of
diseased skin and mucosal membranes of the GI, genitourinary, and respiratory
tracts.
Candida species also contain their own set of well-recognized virulence
factors. Although not well characterized, several virulence factors may contri-
bute to their ability to cause infection. The main virulence factors are surface
molecules that permit adherence of the organism to other structures (e.g., hu-
man cells, extracellular matrix, prosthetic devices), acid proteases, and the
ability to convert to a hyphal form.
As with most fungal infections, host defects also play a significant role in
the development of candidal infections. Numerous host defects are associated
with candidal infections.
Host defence mechanisms against Candida infection and their associated
defects that allow infection are as follows:
— Intact mucocutaneous barriers — Wounds, intravenous catheters, burns,
ulcerations
— Phagocytic cells — Granulocytopenia
— Polymorphonuclear leukocytes — Chronic granulomatous disease
— Monocytic cells — Myeloperoxidase deficiency
— Complement — Hypocomplementemia
— Immunoglobulins — Hypogammaglobulinemia
— Cell-mediated immunity — Chronic mucocutaneous candidiasis, dia-
betes mellitus, cyclosporin A, corticosteroids, HIV infection
— Mucocutaneous protective bacterial florae — Broad-spectrum anti-
biotics
Risk factors associated with candidiasis include the following:
— Granulocytopenia
— Bone marrow transplantation
— Solid organ transplantation (liver, kidney)
— Parenteral hyperalimentation
— Hematologic malignancies
— Foley catheters
— Solid neoplasms
— Recent chemotherapy or radiation therapy
— Corticosteroids
— Broad-spectrum antibiotics
— Burns
— Prolonged hospitalization
— Severe trauma
— Recent bacterial infection
— Recent surgery
— GI tract surgery
— Central intravascular access devices
81— Premature birth
— Hemodialysis
The first step in the development of a candidal infection is colonization
of the mucocutaneous surfaces. The factors outlined above are all associated
with increased colonization rates. The routes of candidal invasion are (1) dis-
ruption of a colonized surface (skin or mucosa), allowing the organisms access
to the bloodstream, and (2) persorption via the GI wall, which may occur
following massive colonization with large numbers of organisms that pass
directly into the bloodstream.
Frequency
— In the US: Candida species are the most common cause of fungal in-
fection affecting immunocompromised patients. Oropharyngeal colonization is
found in 30—55% of healthy young adults, and Candida species may be de-
tected in 40—65% of normal fecal florae.
Three of every 4 women have at least 1 bout of vulvovaginal candidiasis
(VVC) during their lifetime.
In HIV-positive persons who are not receiving highly active antiretrovi-
ral therapy (HAART), more than 90% experience oropharyngeal candidiasis
(OPC) and 10% have at least 1 episode of esophageal candidiasis.
In persons with systemic infections, Candida species are now the fourth
most commonly isolated pathogens from blood cultures.
Clinical and autopsy studies have confirmed a considerable increase in
the incidence of disseminated candidiasis, reflecting a parallel increase in the
frequency of candidemia. This increase is multifactorial in origin and reflects
increased recognition of the fungus, a growing population of patients at risk
(i.e., patients undergoing complex surgical procedures, patients with indwelling
vascular devices), and the improved survival of patients with underlying neo-
plasms or collagen-vascular disease and patients who are immunosuppressed
(3,4).
— Internationally: Similar rates of mucocutaneous and systemic candi-
diasis have been observed worldwide. In fact, throughout the world, Candida
species have replaced Cryptococcus species as the most common fungal patho-
gens affecting immunocompromised hosts.
Mortality/Morbidity
— Mucocutaneous candidiasis: Most candidal infections are mucocuta-
neous and, as such, do not cause mortality. However, in patients with advan-
ced immunodeficiency due to HIV infection, these mucosal infections can be-
come refractory to antifungal therapy and may lead to severe oropharyngeal
and esophageal candidiasis that initiates a vicious cycle of poor oral intake,
malnutrition, wasting, and early death.
82— Candidemia and disseminated candidiasis: Mortality rates for these in-
fections have not improved much over the past few years and remain in the
range of 30—40%. Systemic candidiasis is the cause of more case fatalities
than any other systemic mycosis. More than a decade ago, investigators re-
ported the enormous economic impact of systemic candidiasis in hospitalized
patients. Candidemia is associated with considerable prolongation of length of
stay in the hospital (70 vs. 40 days in patients who are comparable, matched,
and nonfungemic). Although mucocutaneous fungal infections, such as oral
thrush and Candida esophagitis, are extremely common in patients with AIDS,
candidemia and disseminated candidiasis are uncommon (5, 6, 7).
Sex: Colonization with Candida species occurs in equal numbers of males
and females. However, in women, VVC is the second most common cause of
vaginitis.
Age: Candidal colonization is at the highest levels during the age extre-
mes in neonates and in people older than 65 years. In addition, mucocutaneous
candidiasis is also more prevalent in neonates and older adults.
History: Infections due to Candida species can manifest in a wide spec-
trum of clinical syndromes as described below. The clinical presentation can
vary depending on the type of infection and the degree of immunosuppression.
Clinical syndromes associated with Candida infection are the following:
Cutaneous candidiasis syndromes
— Generalized cutaneous candidiasis: This is an unusual form of cuta-
neous candidiasis that manifests as a diffuse eruption over the trunk, thorax,
and extremities. The patient has a history of generalized pruritus, with increa-
sed severity in the genitocrural folds, anal region, axillae, hands, and feet.
Physical examination reveals a widespread rash that begins as individual ve-
sicles that spread into large confluent areas.
— Intertrigo: The patient has a history of intertrigo affecting any site
where the skin surfaces are in close proximity, providing a warm and moist
environment. Pruritic red rash occurs. Physical examination reveals a rash that
begins with vesiculopustules, which enlarge and rupture, causing maceration
and fissuring. The area involved has a scalloped border with a white rim con-
sisting of necrotic epidermis that surrounds the erythematous macerated base.
Satellite lesions are frequently found and may coalesce and extend into larger
lesions (8, 9).
— Metastatic skin lesions: Characteristic skin lesions occur in approxi-
mately 10% of patients with disseminated candidiasis and candidemia. The le-
sions may be numerous or few. Lesions are generally described as erythema-
tous, firm, nontender macronodular lesions with discrete borders. Biopsy speci-
mens of these lesions demonstrate yeast cells, hyphae, or pseudohyphae, and
cultures are positive for Candida species in approximately 50% of the cases.
— Candida folliculitis: The infection is found predominantly in the hair
follicles and, rarely, can become extensive.
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mycosis are associated with immersion of the hands in water and with diabetes
mellitus. The patient has a history of a painful and erythematous area around
and underneath the nail and nail bed. Physical examination reveals an area of
inflammation that becomes warm, glistening, tense, and erythematous and may
extend extensively under the nail. It is associated with secondary nail thicke-
ning, ridging, discoloration, and occasional nail loss (10, 11).
Chronic mucocutaneous candidiasis
Chronic mucocutaneous candidiasis describes a group of Candida infec-
tions of the skin, hair, nails, and mucous membranes that tends to have a pro-
tracted and persistent course.
— History: Most infections begin in infancy or the first 2 decades of
life; onset in people older than 30 years is rare.
’ Most patients survive for prolonged periods and rarely experience
disseminated fungal infections. The most common cause of death is
bacterial sepsis.
’ Chronic mucocutaneous candidiasis is frequently associated with
endocrinopathies, such as the following:
 Hypoparathyroidism
 Addison disease
 Hypothyroidism
 Diabetes mellitus
 Autoimmune antibodies to adrenal, thyroid, and gastric tissues
(approximately 50%)
 Thymomas
 Dental dysplasia
 Polyglandular autoimmune disease
 Antibodies to melanin-producing cells
— Physical examination: Findings reveal disfiguring lesions of the face,
scalp, hands, and nails. This is occasionally associated with oral thrush and vi-
tiligo.
GI tract candidiasis
— Oropharyngeal candidiasis
’ The patient has a history of HIV infection, denture wear, diabetes
mellitus, or frequent use of broad-spectrum antibiotics or inhaled
steroids. Patients may be asymptomatic, but variable symptoms may
include the following:
 Sore and painful mouth
 Burning mouth or tongue
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 Whitish, thick patches on the oral mucosa
’ Physical examination reveals a diffuse erythema and white patches
that appear on the surfaces of the buccal mucosa, throat, tongue,
and gums. The following are the 5 types of OPC:
 Membranous candidiasis: This is one of the most common types
and is characterized by creamy-white curdlike patches on the mu-
cosal surfaces.
 Erythematous candidiasis: This is associated with an erythema-
tous patch on the hard and soft palates.
 Chronic atrophic candidiasis (denture stomatitis): This type is al-
so thought to be one of the most common forms of the disease.
The presenting signs and symptoms include chronic erythema
and edema of the portion of the palate that comes into contact
with dentures.
 Angular cheilitis: An inflammatory reaction, this type is characte-
rized by soreness, erythema, and fissuring at the corners of the
mouth.
 Mixed: A combination of any of the above types is possible.
— Esophageal candidiasis
’ The patient's history usually includes chemotherapy, the use of
broad-spectrum antibiotics or inhaled steroids, or the presence of
HIV infection or hematologic or solid organ malignancy. Patients
may be asymptomatic, but variable symptoms may include the fol-
lowing:
 No oral disease (> 50% of patients)
 Dysphagia
 Odynophagia
 Retrosternal pain
 Epigastric pain
 Nausea and vomiting
’ Upon physical examination, oral candidiasis is nearly always pre-
sent.
— Nonesophageal GI candidiasis
’ Most commonly, the patient's history includes an association with
neoplastic disease of the GI tract. The stomach is found to be the
second most commonly infected site after the esophagus. With less
frequency, patients may have chronic gastric ulcerations, gastric
perforations, or malignant gastric ulcers with concomitant candidal
infection. The third most common site of infection (20%) is the small
bowel. The frequency of candidal infection in the small bowel is
the same as in the large bowel. Approximately 15% of patients de-
velop systemic candidiasis.
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of infection. The diagnosis, however, cannot be made solely on cul-
ture results because approximately 20—25% of the population is
colonized by Candida. The following symptoms may be present:
 Epigastric pain
 Nausea and vomiting
 Abdominal pain
 Fever and chills
 Occasionally, abdominal mass
Respiratory tract candidiasis
The respiratory tract is frequently colonized with Candida species, espe-
cially in hospitalized patients. In ambulatory patients, 20—25% of the popula-
tion is colonized by Candida species.
— Laryngeal candidiasis: This is very unusual but may be a source for
disseminated candidiasis. Laryngeal candidiasis is primarily observed in pati-
ents with hematologic malignancies. The patient may have a sore throat and
hoarseness. Physical examination findings are generally unremarkable, and the
diagnosis is made by direct or indirect laryngoscopy.
— Candida tracheobronchitis: This is a rare form of candidiasis. Most
patients with Candida tracheobronchitis are seropositive for HIV, or are seve-
rely immunocompromised, reporting fever, productive cough, and shortness of
breath. Physical examination reveals dyspnea and scattered rhonchi. The diag-
nosis is generally made after bronchoscopy.
— Candida pneumonia: It does not exist alone and occurs only rarely as
a part of disseminated candidiasis. The most common form is multiple absces-
ses due to hematogenous dissemination of Candida species. The high degree
of colonization and isolation of Candida species from the respiratory tract ma-
kes diagnosing this entity difficult. The patient's history reveals similar risk
factors for disseminated candidiasis, and patients report shortness of breath,
cough, and respiratory distress. Physical examination reveals fever, dyspnea,
and variable breath sounds, from clear, rhonchi to scattered rales.
Genitourinary tract candidiasis
— Vulvovaginal candidiasis: This is the second most common cause of
vaginitis. The patient's history includes vulvar pruritus, vaginal discharge,
dysuria, and dyspareunia. Approximately 10% of women experience repeated
attacks of VVC without precipitating risk factors. Physical examination fin-
dings include a vagina and labia that are usually erythematous, a thick curdlike
discharge, and a normal cervix upon speculum examination.
— Candida balanitis: Patients report itchiness of the penis. Lesions and
whitish patches are present. Candida balanitis is acquired through sexual inter-
course with a partner who has VVC. Physical examination reveals vesicles on
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spread to the thighs, gluteal folds, buttocks, and scrotum.
— Candida cystitis: Many patients frequently are asymptomatic. How-
ever, bladder invasion may result in frequency, urgency, dysuria, hematuria,
and suprapubic pain. Candida cystitis may or may not be associated with the
use of a Foley catheter. Physical examination may reveal suprapubic pain;
otherwise, examination findings are unremarkable.
— Asymptomatic candiduria: Most catheterized patients with persistent
candiduria are asymptomatic, similar to noncatheterized patients. Most patients
with candiduria have easily identifiable risk factors for Candida colonization.
Thus, the distinction between invasive disease and colonization cannot be
made solely on culture results because approximately 5—10% of all urine cul-
tures are positive for Candida.
— Ascending pyelonephritis: The use of stents and indwelling devices,
along with the presence of diabetes, is the major risk factor predisposing pa-
tients to ascending infection. The patient frequently has a history of flank pain,
abdominal cramps, nausea, vomiting, fever, chills, and hematuria, Physical
examination reveals abdominal pain, costovertebral-angle tenderness, and fever.
— Fungal balls: This is due to the accumulation of fungal material in the
renal pelvis. The condition may produce intermittent urinary tract obstruction
with subsequent anuria and ensuing renal insufficiency (12, 13).
— Candidemia
’ Candida species currently are the fourth most commonly isolated
organism in blood cultures, and Candida infection generally is con-
sidered a nosocomially acquired infection. The patient's history
commonly reveals the following:
 Several days of fever that is unresponsive to broad-spectrum anti-
microbials; often the only marker of infection
 Prolonged intravenous catheterization
 A history of several key risk factors (see http://www.emedicine.
com/med/topic264.htm Pathophysiology)
 Possibly associated with multiorgan infection.
’ Physical examination is remarkable for the following:
 Fever
 Macronodular skin lesions (approximately 10%)
 Candidal endophthalmitis (approximately 10—28%)
 Occasionally, septic shock (hypotension, tachycardia, tachypnea).
’ Other causes of candidemia without invasive disease include the
following:
 Intravascular catheter-related candidiasis: This entity usually re-
sponds promptly to catheter removal and antifungal treatment.
 Suppurative thrombophlebitis: For the most part, this is observed
secondary to prolonged central venous catheterization. Suppura-
87tive thrombophlebitis manifests as fever and candidemia, which
persist despite antifungal therapy and catheter removal. Sepsis
also may be present.
 Endocarditis: The frequency of endocarditis has increased in the
past few years. Endocarditis is the most common cause of fungal
endocarditis and is primarily due to Candida albicans (> 60% of
cases). The most common valves involved are the aortic and mi-
tral. The 2 different forms of endocarditis are exogenous, which
is secondary to direct infection during surgery, and endogenous,
which is due to secondary spread during candidemia and dissemi-
nated candidiasis. Endocarditis is frequently associated with 4
main risk factors. These are (1) intravenous heroin use, which is
frequently associated with infection due to Candida parapsilosis;
(2) chemotherapy; (3) prosthetic valves (approximately 50%);
and (4) prolonged use of central venous catheters.
— Disseminated candidiasis: This is frequently associated with multiple
deep organ infections or may involve single organ infection. Unfortunately,
patients with disseminated candidiasis, as many as 40—60% of them, may
have blood culture results negative for Candida species. The history of a pa-
tient with presumptive disseminated candidiasis reveals a fever unresponsive to
broad-spectrum antimicrobials and negative results from blood culture. Phy-
sical examination reveals fever (which may be the only symptom) with an
unknown source and sepsis and septic shock.
— Candida endophthalmitis: The 2 forms of Candida endophthalmitis
are the exogenous and the endogenous form. Exogenous endophthalmitis is as-
sociated with either accidental or iatrogenic (postoperative) injury of the eye and
inoculation of the organism from the environment. Endogenous endophthal-
mitis results from hematogenous seeding of the eye. It is found in 10—28% of
the patients with candidemia. The use of hematogenous candidal endophthal-
mitis as a marker of widespread disseminated candidiasis is important.
’ The patient's history reveals a broad range of manifestations.
 Eye injury
 Ophthalmic surgery
 Underlying risk factors for candidemia
 Asymptomatic and detected upon physical examination
 Ocular pain
 Photophobia
 Scotomas
 Floaters
’ Physical examination reveals fever.
’ Upon funduscopic examination, early lesions are the size of a pin-
head, are off-white in color, and are found in the posterior vitreous
with distinct margins and minimal vitreous haze. Classic lesions are
large and off-white, similar to a cotton-ball, with indistinct borders
covered by an underlying haze. Lesions are 3-dimensional and ext-
88end into the vitreous off the chorioretinal surface. They may be sin-
gle or multiple.
— Renal candidiasis
’ This is most frequently a consequence of candidemia and dissemi-
nated candidiasis. Patient's history includes fever that is unrespon-
sive to broad-spectrum antimicrobials. Frequently, patients are asymp-
tomatic and lack symptoms referable to the kidney.
’ Physical examination is generally unremarkable, and renal candidia-
sis is diagnosed after urinalysis and renal biopsy. Otherwise, this
condition is commonly diagnosed at autopsy.
’ Physical examination reveals the following:
 Fever
 Nuchal rigidity
 Confusion
 Coma
— Candida arthritis, osteomyelitis, costochondritis, and myositis
’ In the past, musculoskeletal infections were rare; currently, they are
more common, due to the increased frequency of candidemia and
disseminated candidiasis. The most common sites of involvement
are the knee and vertebral column. The pattern of involvement is si-
milar to the pattern observed in bacterial infections. The infection
may be exogenous or endogenous. The exogenous infection is fre-
quently due to direct inoculation of the organisms, such as postope-
rative infection or trauma. Affected sites include the following:
 Ribs and leg bones (< 20 years)
 Vertebral column and paraspinal abscess (adulthood)
 Flat bones (any age group)
 Sternum — Generally observed postoperatively after cardiac surgery
’ The patient frequently is asymptomatic, and the patient's history re-
veals underlying risk factors of disseminated candidiasis and loca-
lized pain over the affected site. The physical examination is fre-
quently unremarkable; otherwise, it may reveal tenderness over the
involved area, erythema, and bone deformity, occasionally with a
draining sinus.
 Arthritis: Generally, arthritis is a complication of disseminated
candidiasis, but it may be caused by trauma or direct inoculation
due to surgery or steroid injections. Most cases are acute and be-
gin as a suppurative synovitis. A high percentage of cases pro-
gress to osteomyelitis. In addition, developing Candida arthritis
after joint replacement is not uncommon.
 Osteomyelitis: The 2 forms of osteomyelitis are exogenous infec-
tion and endogenous infection. The exogenous infection is fre-
quently due to either direct inoculation of the organisms, such as
89through postoperative infection, trauma, or steroid injections. The
endogenous form of osteomyelitis is generally a complication of
disseminated candidiasis. Most cases, due to hematogenous see-
ding, infect the vertebral disks and progress to diskitis with ex-
tension into the vertebrae from contiguous spread. Other bones
affected include the wrist, femur, scapula, and proximal humerus.
 Costochondritis: This is rare and usually has 2 forms. Costochon-
dritis usually results from either hematogenous spread or direct
inoculation during surgery (median sternotomy). Frequently, co-
stochondritis is associated with localized pain over the involved
area.
 Myositis: This occurs infrequently, and an association with disse-
minated candidiasis is common. Most patients are neutropenic.
People with myositis have a history of muscular pain.
— Myocarditis-pericarditis: This is due to hematogenous spread in asso-
ciation with disseminated disease and is rarely due to direct extension from the
sternum or esophagus. Myocarditis-pericarditis occurs as diffuse abscesses
scattered throughout the myocardium with normal cardiac tissue. In persons
with disseminated candidiasis, the rate has been documented to be as high as
50%. The patient's history reveals serious complications in 10—20% of the
cases without valve disease, fever and chills. Physical examination reveals fe-
ver, hypotension, shock, tachycardia, and new murmurs or rubs (changes in
previously detected murmurs).
— Candida peritonitis
’ The patient's history frequently reveals an association with GI tract
surgery, viscous perforation, or peritoneal dialysis. Candida perito-
nitis tends to remain localized, and only in 15% of the cases does
the infection disseminate into the blood stream. The range of mani-
festations is broad and includes fever and chills, abdominal pain
and cramping, nausea and vomiting, and constipation.
’ Physical examination is significant for the following:
 Fever
 Abdominal distention
 Abdominal pain
 Absent bowel sounds
 Rebound tenderness
 Localized mass
— Candida splenic abscess and hypersplenism: Both are manifestations
of disseminated candidiasis and are usually simultaneously associated with li-
ver involvement. Manifestations of hypersplenism are common (see
http://www.emedicine.com/med/topic264.htm Hepatosplenic candidiasis).
— Candida cholecystitis: This is rare and generally associated with bac-
terial cholangitis and ascending cholangitis. Most commonly, Candida chole-
cystitis is diagnosed at the time of surgery when a culture is obtained.
90— The medically significant Candida species include the following:
’ C. albicans, the most common species identified (50—60%)
’ C. glabrata (15—20%)
’ C. parapsilosis (10—20%)
’ C. tropicalis (6—12%)
’ C. krusei (1—3%)
’ C. kefyr (< 5%)
’ C. guilliermondi (< 5%)
’ C. lusitaniae (< 5%)
’ C. dubliniensis, primarily recovered from patients who are positive
for HIV.
— C. glabrata and C. albicans account for approximately 70—80% of
yeast isolated from patients with invasive candidiasis. C. glabrata has recently
become important because of its increasing incidence worldwide, and it is
intrinsically less susceptible to azoles and amphotericin B.
— C. krusei is important because of its intrinsic resistance to ketocona-
zole and fluconazole (Diflucan). Additionally, it is also less susceptible to all
other antifungals, including itraconazole (Sporanox) and amphotericin B.
— Another important Candida species is C. lusitaniae; although not as
common as some Candida species, it is of clinical significance because it is
frequently resistant to amphotericin B, although it remains susceptible to azo-
les and echinocandins.
— C. parapsilosis is an important species to consider in hospitalized pa-
tients with vascular catheters.
— C. tropicalis has been considered an important cause of candidemia in
patients with cancer (leukemia), and in those who have undergone bone mar-
row transplantation.
Lab Studies
— Unfortunately, findings from the laboratory studies are often nonspe-
cific. Clinicians are required to act definitively and early, based on a high
index of suspicion. In the past, many patients with life-threatening candidiasis
died without receiving antifungal therapy. Patients who remain febrile despite
broad-spectrum antibiotic therapy, with either persistent neutropenia or other
risk factors and persistent leukocytosis, should be suspected of having syste-
mic candidiasis. To be effective, therapy should be provided early and empiri-
cally in such patients.
— Cultures of nonsterile sites, although not useful for establishing a di-
agnosis, may demonstrate high degrees of candidal colonization. Positive cul-
ture results from sterile sites should be considered significant and as an evi-
dence of infection.
— Mucocutaneous candidiasis
91’ Wet mount, scrapings or smears obtained from skin, nails, oral mu-
cosa, or vaginal mucosa are examined under the microscope for
hyphae, pseudohyphae, or budding yeast cells.
’ With a potassium hydroxide smear, the Gram stain methylene blue
is useful to demonstrate fungal cells, directly.
’ Cultures of affected nails are helpful to diagnose onychomycosis
versus noninfectious causes.
— Candidemia and disseminated candidiasis
’ Blood cultures are helpful but are positive in only 50—60% of the
cases of disseminated disease.
’ Urinalysis may be helpful, and results may be indicative of either
colonization or renal candidiasis.
’ The serum 1—3 D-glucan detection assay (Glucatell, Fungitell) is a
nonculture test, which was approved for use in the United States in
May 2004. This assay measures the level of beta-glucan (a fungal
cell wall component). In a large multicenter study, the assay had a
high specificity and positive predictive value with highly reprodu-
cible results.
’ Cultures of nonsterile sites, although not useful for establishing a
diagnosis, may be useful for initiating antifungal therapy in patients
with fever that is unresponsive to broad-spectrum antimicrobials.
Therefore, appropriate interpretation is required. Positive results from
blood cultures and cultures from other sterile sites imply the pre-
sence of invasive disease. Always consider positive results from
these sites to be significant and to be an evidence of infection.
’ GI, respiratory, and urinary tract culture results positive for Can-
dida may not represent invasive disease. However, consider the GI,
respiratory, and urinary tract sites of colonization.
— Cutaneous candidiasis: Use a wet mount. Scrapings or smears ob-
tained from skin or nails are examined under the microscope for hyphae,
pseudohyphae, or budding yeast cells. Potassium hydroxide smears are also
useful.
— Genitourinary candidiasis: Perform a urinalysis. Evidence of WBCs,
RBCs, protein, and yeast cells can be found. Additionally, urine fungal cultu-
res are useful.
— Respiratory tract candidiasis
’ Sputum Gram stain demonstrates WBCs and yeast cells.
’ Sputum culture demonstrates Candida species.
’ Lung biopsy is mandatory to establish definitively the diagnosis of
respiratory tract candidiasis, because the respiratory tract is fre-
quently colonized with yeast.
— GI candidiasis: Endoscopy, with or without biopsy is necessary to
establish the diagnosis.
— Focal hepatosplenic candidiasis: Elevation of the serum alkaline pho-
sphatase level is common.
92— Species identification
’ C. albicans, C. dubliniensis, and C. stellatoidea can be identified
morphologically by germ-tube formation (hyphae are produced from
yeast cells after 2—3 h of incubation) or biochemical assays.
’ CHROMagar Candida allows presumptive identification of several
Candida species by using color reactions in specialized media that
demonstrate different colony colors, depending on the species of
Candida.
’ API 20C and API 32C are biochemical assays that allow the identi-
fication of different Candida species with more precision. These
assays evaluate the assimilation of a number of carbon substrates
and generate profiles used in the identification of different fungal
species.
— Antifungal susceptibility testing
’ In vitro susceptibility testing for Candida species is now standar-
dized, using the National Committee for Clinical Laboratory Stan-
dards (NCCLS) microbroth dilution methodology (NCCLS M27-A2).
’ Although not used as a standard of care, this method may be help-
ful in guiding difficult therapeutic decisions. Most of the difficult
decisions are observed in antifungal, refractory, oral, or esophageal
candidiasis in patients with advanced HIV disease.
— Nonculture Candida detection assays
’ The Candida mannan assay has a sensitivity of 31—90% (less for
non-albicans Candida species).
’ The Candida heat labile antigen assay has a sensitivity of 10—
71%.
’ The D-arabinitol assay has a sensitivity of 50% but is not useful for
infection with C. krusei or C. glabrata.
’ The enolase assay has a sensitivity of 55—75%, which improves
with serial testing.
’ The 1—3 beta-D-glucan assay is an amebocyte lysis assay with a
sensitivity of 75—100% and a specificity of 88—100% (broad-
-spectrum assay that detects Aspergillus, Candida, Fusarium, Acre-
monium, and Saccharomyces species). Beta-D-glucan is a compo-
nent of the cell wall of a wide variety of fungi and can be detected
by its ability to activate factor G of the horseshoe crab coagulation
cascade. The Fungitell assay is used in the evaluation of invasive
fungal infections caused by the species mentioned above to guide
diagnosis. It does not detect infections caused by Cryptococcus
neoformans and Zygomycetes.
— Molecular assays such as polymerase chain reaction tests and DNA
probes are still under development and in the early reserach stage.
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Rezime
Mikrobiologija predstavqa nauku koja se razvija progresivno. Najnovija
istraÿivawa pokazuju posebne izmene na poqu dijagnoze i odgovarajuãe terapije.
Tokom posledwe dve dekade, kandida specijes dobile su na znaåaju kao uzroåni-
ci morbiditeta i mortaliteta kod hospitalizovanih pacijenata. Izolacija kan-
dida iz krvi ili drugih sterilnih podruåja iskquåujuãi urinarni trakt, potvr-
ðuje invazivnost kandida. Kandida vrste nalaze se na åetvrtom mestu najåešãih
uzroånika koji izazivaju infekcije preko krvi (kandidemija) u SAD, a naroåito
na odeqewima intenzivne nege gde se kod 1% pacijenata radi o dubokim infek-
cijama uzrokovanim kandida vrstama. Uprkos uvoðewu novijih antikandida age-
nasa, invazivna kandidijaza ostaje i daqe izazov za kliniåare i mikrobiologe.
Razlozi za propuste u dijagnostici ukquåuju nespecifiåne faktore rizika i
kliniåke manifestacije, slabu osetqivost tehnika kultivacije kandida i pri-
menu invazivnih metoda za uzorkovawe bolesniåkog materijala u sluåaju duboke
kandidijaze. Åak i kada se invazivna kandidijaza dijagnostikuje, kultivacija
kandida traje 2—3 dana, što doprinosi porastu mortaliteta. Preventivno da-
vawe (empirijska terapija) antikandida agenasa moÿe poboqšati preÿivqava-
we pacijenata. Selektivno i neselektivno davawe antikandida agenasa u vidu
profilakse primewuje se na nekim odeqewima intenzivne nege. Ostaje kontro-
verzna uloga antikandida profilakse kod takvih pacijenata, s obzirom na wi-
hov odgovor na antimikrobnu terapiju. Vodiå za aktuelni tretman kandidijaze
Udruÿewa za infektivne bolesti SAD (IDSA) nije posebno definisao da li
empirijska antikandida terapija treba da se primeni kod imunokompetentnih
pacijenta. Posebno je teško primeniti optimalnu antikandida strategiju kod
hospitalizovanih pacijenata na odeqewima intenzivne nege.
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